The US Food and Drug Administration has expanded the approval of Faslodex, a hormonal therapy for the treatment of breast cancer first approved in 2002.
After clinical trials demonstrated its safety and efficacy, the FDA approved a new treatment that is the first to combine standard care with a new therapy for adult patients with hyperuricemia associated...
After clinical trials demonstrated its safety and efficacy, the FDA approved a new treatment that is the first to combine standard care with a new therapy for adult patients with hyperuricemia associated...
After clinical trials demonstrated its safety and efficacy, the FDA approved a new treatment that is the first to combine standard care with a new therapy for adult patients with hyperuricemia associated...
The US Food and Drug Administration granted regular approval to a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The US Food and Drug Administration granted regular approval to a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The US Food and Drug Administration granted regular approval to a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
